Premature ovarian failure is a relatively common clinical condition, and carries important long-term health consequences. Estrogen replacement is recommended to alleviate unpleasant hypo-estrogenic symptoms and reduce long-term health risks. However, the most suitable form of estrogen replacement, and the exact effects of no treatment, is unknown. Surprisingly, little research has been carried out in this area. We describe the design of an ongoing clinical trial that will address these issues so that we can begin to provide evidence-based care for affected women.
PitkinJ, ReesMCP, GrayS, Management of premature menopause. Menopause Int2007;13:44–5
2.
CoulamCB, AdamsonSC, AnnegersJF. Incidence of premature ovarian failure. Obstet Gynecol1986;67:604–6
3.
AtsmaF, BartelinkM-LEL, GrobbeeDE, van der SchouwYT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause2006;13:265–79
4.
van der SchouwYT, van der GraafY, SteyerbergEW, EijkemansJC, BangaJD. Age at menopause as a risk factor for cardiovascular mortality. Lancet1996;347:714–8
5.
van KasterenYM, SchoemakerJ. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update1999;5:483–92
NelsonLM, CovingtonSN, RebarRW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril2005;83:1327–32
8.
Menopause and Hormone Replacement – study group statement. Consensus Views arising from the 47th Study Group: Menopause and Hormone Replacement: Royal College of Obstetricians and Gynaecologists, 2004. See: http://www.rcog.org.uk/womens-health/clinical-guidance/menopause-and-hormone-replacement-study-group-statement (last accessed 1 March 2010)
